Table S1. Univariable and multivariable analysis of predictors of MTX non-response for those with active disease at baseline. Table S2. Univariable and multivariable analysis of predictors of failure to achieve low disease activity at 6Â months. Figure S1. Calibration plot for multivariable prediction model for non-response to MTX for those not in remission at baseline. Figure S2. Calibration plot for multivariable prediction model for non-response to MTX for those with active disease at baseline. Figure S3. Calibration plot for multivariable prediction model for failure to achieve low disease activity. (DOCX 60 kb
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...
Introduction: Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis (RA), ye...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Annual changes in disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and...
Summary of patient disposition in the open-label and double-blind periods. CDAI Clinical Disease Act...
Comparison of mean change in outcome measurement scores between early period (0–6 weeks) and late pe...
Table S1. Summary of clinical response after 4 and 12 weeks of treatment (mITT population plus first...
OBJECTIVE: The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMAR...
Table S4. Adverse events leading to MTX failure for the subgroup that fulfils 2010 ACR/EULAR RA clas...
Table S3. Baseline clinico-demographic variables according to reason for MTX failure (DOCX 15 kb
Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical di...
Contains fulltext : 110572.pdf (publisher's version ) (Closed access)Background: T...
Objectives: In rheumatology, there is a clinical need to identify patients at high risk (>50%) of...
ObjectiveThe objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD ...
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...
Introduction: Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis (RA), ye...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Annual changes in disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and...
Summary of patient disposition in the open-label and double-blind periods. CDAI Clinical Disease Act...
Comparison of mean change in outcome measurement scores between early period (0–6 weeks) and late pe...
Table S1. Summary of clinical response after 4 and 12 weeks of treatment (mITT population plus first...
OBJECTIVE: The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMAR...
Table S4. Adverse events leading to MTX failure for the subgroup that fulfils 2010 ACR/EULAR RA clas...
Table S3. Baseline clinico-demographic variables according to reason for MTX failure (DOCX 15 kb
Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical di...
Contains fulltext : 110572.pdf (publisher's version ) (Closed access)Background: T...
Objectives: In rheumatology, there is a clinical need to identify patients at high risk (>50%) of...
ObjectiveThe objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD ...
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...
Introduction: Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis (RA), ye...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...